Our Company
We discovered and developed bio-identical, cost-effective, valuable proteins, including recombinant human Basic Fibroblast Growth Factor (RH bFGF). These cell signaling molecules address challenging medical conditions in humans, including treating androgenetic alopecia.
ReGen Factor scientists track records that include applying a scientifically based, data-driven approach to the discovery of novel, bio-identical and cost-effective production methods for human-derived growth factors for human and animal health applications using our proprietary production method named NBPES (Novel Bioidentical Protein Expression System).
Our current focus is on two unique clinical assets in hair loss and wound healing. We have two high-value, inter-related programs in hair loss for the human market and wound healing which we are co-developing for the human and companion animal markets.
Treatment of Androgenetic Alopecia
Our lead hair regrowth product for the treatment of androgenetic alopecia in both men and women, PepFactor Scalp, is a novel, bio-identical, recombinant human basic Fibroblast Growth Factor that is administered topically and promotes “angiogenesis activity with the potential to treat a broad range of applications including androgenetic alopecia and wound healing, either as a monotherapy or in combination with small molecules like copper peptide to block testosterone in the instance of treating hair loss from androgenetic alopecia.
DUHEALUP
Human clinical trials with PepFactor Scalp for androgenetic alopecia are in late-stage planning. Our drug candidate, DUHEAL, will be investigated for its potential across a range of hard-to-heal wounds, including diabetic ulcers and bedsores.
In companion animals, DUHEAL has been registered and is marketed (branded as DUHEALUP ®*) as a veterinary pharmaceutical for the treatment of canine wounds in the US, Europe, and Australia. Clinical trials are in the early stages of planning to determine the efficacy of DUHEALUP in other applications, including gum disease in canines and other species.
Our lead wound healing candidate, DUHEALUP, is a novel, bio-identical large molecule formulated as a topical gel. Preclinical models and veterinary clinical data show its potential to treat a wide range of difficult-to-manage wounds, including chronic non-healing and traumatic acute injuries and burns. This program is currently in the early clinical stage for veterinary applications and in formal preclinical development for humans. Learn more about our wound healing program.
We have strong intellectual property protection for all our products.
All our products are protected by patent encompassing both matter composition and use. We also have an ongoing program of new patent applications and patented extension activities.
A Discovery Pipeline Underpins Our Potential for Long-Term Growth
Our NBPES discovery technology provides future opportunities to expand our portfolio of therapeutic indications. The first of these new areas, a discovery stage, next-generation acne treatment, is ready to progress to development once our current clinical products are commercialized.
We discovered and developed bio-identical, cost-effective, valuable proteins, including recombinant human Basic Fibroblast Growth Factor (RH bFGF). These cell signaling molecules address challenging medical conditions in humans, including treating androgenetic alopecia.
ReGen Factor scientists track records that include applying a scientifically based, data-driven approach to the discovery of novel, bio-identical, and cost-effective production methods for human-derived growth factors for human and animal health applications using our proprietary production method named NBPES (Novel Bioidentical Protein Expression System).
Our current focus is on two unique clinical assets in hair loss and wound healing. We have two high-value, inter-related programs in hair loss for the human market and wound healing which we are co-developing for the human and companion animal markets.
Our lead hair regrowth product for the treatment of androgenetic alopecia in both men and women, PepFactor Scalp, is a novel, bio-identical, recombinant human basic Fibroblast Growth Factor that is administered topically and promotes “angiogenesis activity with the potential to treat a broad range of applications including androgenetic alopecia and wound healing, either as a monotherapy or in combination with small molecules like copper peptide to block testosterone in the instance of treating hair loss from androgenetic alopecia.
Human clinical trials with PepFactor Scalp for androgenetic alopecia are in late-stage planning. Our drug candidate, DUHEAL, will be investigated for its potential across a range of hard-to-heal wounds, including diabetic ulcers and bedsores.
In companion animals, DUHEAL has been registered and is marketed (branded as DUHEALUP ®*) as a veterinary pharmaceutical for the treatment of canine wounds in the US, Europe, and Australia. Clinical trials are in the early stages of planning to determine the efficacy of DUHEALUP in other applications, including gum disease in canines and other species.
Our lead wound healing candidate, DUHEALUP, is a novel, bio-identical large molecule formulated as a topical gel. Preclinical models and veterinary clinical data show its potential to treat a wide range of difficult-to-manage wounds, including chronic non-healing and traumatic acute wounds and burns. This program is currently in the early clinical stage for veterinary applications and in formal preclinical development for humans. Learn more about our wound healing program.
